Zejula 100 mg film-coated tablets clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.
This study is testing different ways to use a new drug called azenosertib (also known as ZN-c3) for women with ovarian cancer that has become resistant to common treatments. It aims to find the safest and most effective dose, whether used alone or with another drug called niraparib.
For: Platinum-Resistant Ovarian CanceFrance - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours
This study is looking at two new medicines, Zejula (niraparib) and JEMPERLI (dostarlimab), for children and young people with solid tumours that have come back or not responded to other treatments. The main goal is to find a safe dose and see if they work together.
For: Solid TumoursSpain · Germany · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors (NIRADO)
This study is testing two medicines, JEMPERLI and Zejula, together to see if they can help people with certain types of cancer. Doctors want to know how well this combination shrinks tumors and if it's safe to use. It's a next step in finding new cancer treatments.
For: DNA repair-deficient or platinum-sensitive solid tumorsFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.
This study looks at a new drug, GSK4524101, combined with an existing cancer drug, niraparib (Zejula), for adults with solid tumours. It aims to find a safe dose and see how well the combination shrinks tumours and manages cancer.
For: NeoplasmsEstonia · Czechia · Spain